58 9 [ 2] [ 3] ( Gelidium amansi), [ ( ) ], 1. 2 ; [ 4] ( Gracilaria lemaneiformis), w( ) w( ) = 1 20, ; EDTA-Na gl h KIHO [ 5] [ 6]

Size: px

Start display at page:

Download "58 9 [ 2] [ 3] ( Gelidium amansi), [ ( ) ], 1. 2 ; [ 4] ( Gracilaria lemaneiformis), w( ) w( ) = 1 20, ; EDTA-Na gl h KIHO [ 5] [ 6]"

堰曹
7 years ago
Views:

1 South China Fisheries Science Vol. 9, No. 3 Jun., 2013 doi: / j. issn , 2 2 2,, ( 1., ; 2., ) :, (O 2 - ) ( OH) ( DPPH) ;,, [ ( TC) ( TG) ( HDL-C) ( LDL-C) ], OH ; TCTGLDL-C, HDL-C, : ; ; ; : R : A : ( 2013) Study on antioxidation, animal experiments of hyperglycemia and hyperlipemia of agaropectin from Gracilaria lemaneiformis LIU Qiufeng 1, 2, WU Chengye 2, SU Yongchang 2 ( 1. College of Food Science, Fujian Agriculture and Forestry University, Fuzhou , China; 2. Fisheries Research Institute of Fujian, Xiamen , China) Abstract: This paper aims at investigating the role agaropectin plays in hyperglycemia, hyperlipemia and antioxidation. We studied the cleaning effect ofo 2 -, OH and DPPH, based on which vitro antioxidation was assessed. We also researched hyperglycemia and hyperlipidemia by making use of alloxan to build diabetic model, and hyperlipidemia fodder to build hyperlipemia model, and conducted animal experiments with different doses of agaropectin so as to assay fasting blood glucose, LDL-C), effect, rat s blood fats ( TC, TG, HDL-C and as well as biochemical indexes of serums and livers. The study of vitro antioxidation reveals that agaropectin has antioxidant functioning especially well on scavengingoh. Animal experiments show that agaropectin can significantly reduce fasting plasma glucose value in hyperglycemia mice, and decrease the content of TC, TG and LDL-C contained in hyperlipidemia rats, which indicates that agaropectin really has an effect on hyperglycemia and hyperlipemia. Key words: agaropectin; antioxidant ability; hyperglycemia; hyperlipemia,,,, [ 1],, : ; : : ( ) : ( ),,, qfeng. liu@ 163. com : ( ),,, wcy@ fjscs. ac. cn

2 58 9 [ 2] [ 3] ( Gelidium amansi), [ ( ) ], 1. 2 ; [ 4] ( Gracilaria lemaneiformis), w( ) w( ) = 1 20, ; EDTA-Na gl h KIHO [ 5] [ 6] [ 7 ] 53, 1. 3, (O 2 - ) ( MDA) O 2 -,, [ 9] 0. 1 moll - 1, ( ph 8. 04) 3. 5 ml 15 ml,,, 1 ml, 10 mmoll , ml,, 10 mmoll - 1,, 325 nm,, ( OD), 30 s ( A 1 ), 30 s 3. 5 min( A 2 ), ( 2 mgml mg 1 mgml mgml mgml mg 1. 1 ml mgml - 1 ) 1 ml,, OD, ; ( DPPH) ( Sigma ) ; ( Pfrizer Pharmaceuticals LLC ) ; SO 0 = A 2 - A 1 ; C 1 = SO 0 - SO 1 100% 3 SO 0 ( C 1 O 2 - ( % ) ; A 2 ) ; ( ) 3. 5 OD; A OD; SO 0 ( TC) ; SO 1 ( TG) ( HDL-C) ( LDL-C) (OH) ( T-SOD) OH ( GSH-Px) ( [ 10 ] 9 mmoll - 1 ) SPS ( KM) (, g) Wistar (, g) ; ( 10% 10% 1% 0. 3% 78. 7% ) ml mgml mgml mg ( ) ml mgml mgml mg BS124S [ ( ) ml ml mg mgml - 1 ) 1 ] ; 752PC ( ml,, h, 510 ) ; SSW-600-2S nmod, A H 2 O 2, ( ) ; OD A 0 ;, OD XW-80A ( A ) ; One Touch Ultra [ 8 ], ml ml mg ml mg mgml ( FeSO 4 ) 8. 8 mmoll - 1 ( H 2O 2 ) 9 mmoll ml 15 ml, ( 0. 2 mgml mg

3 3 : 59 C 2 = A - ( A - A 0 ) A 100% C 2 OH ( % ) ; A OD; A OD; A 0 H 2 O 2 OD; DPPH [ 14 ] DPPH SHAMA BHAT [ 11 ] ( 2 mg 5 h,, 20 min 2. 0 g ml mgml mgml mg ml mgml mgml mgml mg ml mg ml mgml - 1 ) , ml 15 ml, 0. 1, mmoll - 1 DPPH 4 ml, 517 nm OD, DPPH, OD A 0 ; OD A C 3 = A - ( A - A 0 ) A, 30 min, A ,, ( GSP) 100% C 3 DPPH ( % ) ; A OD; A OD;, 5 2 A 0 DPPH OD 1. 4, 2, [ ] TCTGHDL-C LDL-C 4, c( TC), 3 d 12 h, > 1. 8 mmoll - 1 c( TG) >1. 8 mmoll - 1 ( kg - 1 ), 200 mgkg - 1 ( ) 6,, TC ( 2% TGHDL-C LDL-C 4, 1 mmoll - 1, d, 1, [ 14] h, 1 kg - 1 ( ), ,, 2 h) 3 d ( 5 h ),, TC ( 2), 10, c mmoll - 1 ( TC) 1 mmoll - 1, , ( 1), 1,, 1. 5 [ ] d 5 2 2, 1 Tab. 1 Design of hypoglycemic animal experiment pharmaceutical / mgkg - 1 dose diabetic model ( DM) - drug control ( DC) 5 normal control ( NC) - agaropectin low-dose ( SPS-L) 200 agaropectin mediu-dose ( SPS-M) 500 agaropectin high-dose ( SPS-H) 800

4 Tab. 2 Design of hypolipidemic animal experiment / gkg - 1 feed pharmaceutical dose normal control ( NC) - normal control-agaropectin ( NC-S) hyperlipidemia model ( HL) - drug control ( DC) agaropectin low-dose ( SPS-L) agaropectin mediu-dose ( SPS-M) agaropectin high-dose ( SPS-H) [ 14 ] h,,, TCTGHDL-CLDL-C T-SODGSH-Px ( MDA) ( NO) ,,, 4, r min min, HDL-CLDL-CT-SODGSH-PXMDA NO SPSS 17. 0, ( X SD), 1 ( 0 d 28 d),, OH Fig. 1 Effect of agaropectin on scavenging superoxide anion radicals IC mgml mgml - 1 OH ( P < 0. 01), 3. 0 mgml mgml - 1, O mg ml - 1,, V C OH IC mg O 2 - ( 1), ml - 1[ 5, 17], ( P > 0. 05) V C OH O 2 - ( P < 0. 01) V C, OH 19 mgml - 1 O 2 - OH 50% 50%, O DPPH 2 20 mg ( IC 50 ) 19 mgml - 1 [ 4 ] C( V C ) ml - 1,, Vc IC mg ml - 1, O 2 -, O 2 - DPPH ( P < OH mg ml - 1 OH 50%, DPPH IC 50 ( 2), 3. 6 mg ml - 1 OH 100%, DPPH ( 3), 0. 01) 17 mgml - 1 DPPH 17 mgml - 1 V C DPPH 50% 5. 0 mgml - 1 [ 4, 18 ], DPPH

5 3 : 61 Fig Effect of agaropectin on scavenging hydroxyl free radicals Fig. 3 Effect of agaropectin on scavenging DPPH , , ( P < 0. 01), ( 0 d),, ( P <0. 05), ( P > 0. 05) ;, ( 4 ) 28 d DCSPS-LSPS-M ( P > SPS-H, 0. 05) ( 3) ( 0 d) 28,, DM, ( P < 0. 05) ; ( P < 0. 01), DCSPS-LSPS-MSPS-H DM DM 23. 2%, DCSPS-LSPS-M SPS- H DM 9. 5% 6. 7%9. 2% 10. 3%, SPS-H DM ( P < 0. 01), SPS-M ( P <0. 05) ( P < 0. 05),,,, ( P < 0. 01), NC ( P < 0. 01) ;, DC SPS-H 3 Tab. 3 ( X SD) Effect of agaropectin on weight in mice / g body weight 0 d 7 d 14 d 21 d 28 d / g / % weight rate of weight growth growth ( DM) ** ** ** ** ** 5. 7 ab ( DC) ** ** ** ** ** 8. 2 ab ( NC) ## ## ## ## ## 9. 3 ab ( SPS-L) ** ** ** ** ** 7. 6 ab ( SPS-M) ** ** ** ** ** 8. 1 ab ( SPS-H) ** ** ** ** ** # 8. 7 ab : NC, *. ( P <0. 05), **. ( P < 0. 01) ; DM, #. ( P < 0. 05), ##. ( P < 0. 01) ;, aa. ( P < 0. 05), ab. ( P < 0. 01) ; Note: ompared with NC, *. significant difference ( P < 0. 05), **. very significant difference ( P < 0. 01) ; Compared with DM, #. significant difference ( P < ), ##. very significant difference ( P < 0. 01) ; Compare between all s, aa. significant difference ( P < 0. 05), ab. very significant difference ( P <0. 01) ; the same case in the following tables.

6 ( X SD) Tab. 4 Effect of agaropectin on lowering blood-glucose in mice mmoll d 7 d 14 d 21 d 28 d difference value ( DM) ** ** ** ** ** 6. 2 ab ( DC) ** ** # ** ## ** ## ** ## 8. 5 aa ( NC) ## ## ## ## ## 0. 3 ( SPS-L) ** ** ** # ** ## ** ## 4. 2 ( SPS-M) ** ** ** # ** ## ** ## ( SPS-H) ** ** ** ## ** ## ** ## 7. 4 aa 6. 2 ab : Note: 5 ( X SD) Tab. 5 Effect of agaropectin on load glucose tolerance in mice mmoll h 0. 5 h 2 h ( DM) * * aa ( DC) ## # ( NC) ** ## ** ## ** ## ( SPS-L) # ( SPS-M) # # ( SPS-H) ## ## DC Compared with DC ,, ( 0 h) DM, ( 6) DCNCSPS-H ( P < 0. 01), SPS-LSPS-M ( P <0. 05) ; DC, DM ( P <0. 05), NC DM, NC ( P < 0. 01) ( 5) 2 h DM ( P <0. 05) ; DM DCNCSPS-LSPS-M SPS-H 0, DCNCSPS-MSPS-H h ( P > 0. 05), DM ( P < 0. 01), SPS-L ( P <0. 05) ( P < 0. 05) ( 7) NC GSP, DCSPS-LSPS-M SPS-H ( P > 0. 5), DCNCSPS-H DM, ( P < 0. 05), DM NC ( P > 0. 05), 2. 3, ; DCNCSPS-H DM TCTG ( P < 0. 01) ( ( P < ), SPS-L SPS-M DM ( P < ( P <0. 01) ( 9), 0. 05), DCSPS-LSPS-MSPS-H NC ( P > 0. 05), SPS-H NC ( P < 0. 05), HL,, ( P > 0. 05), ; GSP DCSPS-H GSP 8), HDL-C ( P < 0. 01), LDL-C ( 0 d) DCSPS-LSPS-M DCNCSPS-LSPS-MSPS-H 28 d, DCSPS-LSPS-M NC, DM NC SPS-H TCTG, HL,

7 3 : 63 6 ( X SD) Tab. 6 Effect of agaropectin on index of spleen, thymus and liver of diabetic mice g liver index spleen index thymus index ( DM) * ** * ( DC) # ## ( NC) # ## # ( SPS-L) # ( SPS-M) # ( SPS-H) # ## ( X SD) Tab. 7 Measurements of GSP, liver glycogen and insulin in serum c( ) / mmoll - 1 glutathion peroxidase ( GSP) w( ) / mgg - 1 hepatic glycogen / miul - 1 serum insulin ( DM) * * ** ( DC) ## ## ## ( NC) # # ## ( SPS-L) # ( SPS-M) ## ( SPS-H) ## ## ## DCSPS-LSPS-M TC NC DCSPS-LSPS-MSPS-H g ( P >0. 05), SPS-H TC g g98. 4 g g97. 5 g98. 7 mmoll - 1 ( P < 0. 01), SPS-LSPS-MSPS-H TG NC ( P > 0. 05), DC mmoll - 1 ( P < 0. 05), TCTG HL ( P < ) ;, ( P < 0. 05), NC-S NC DCSPS-LSPS-MSPS-H 0 d TCTG ( P < 0. 01), HL TC ( P < 0. 05) TG ( P >, 0. 05), TCTG ; DC SPS-LSPS-MSPS-H 0 d HDL-C ( P <0. 01), LDL-C NC-SDCSPS-MSPS-H ( P < 0. 01) HL HDL-C ( P NC ( P > 0. 05), SPS-L > 0. 05), LDL-C ( P < 0. 01), HDL-CLDL-C ( P <0. 01), 8 9,, TCTG, HDL-C, LDL-C, SPS-H GSH-Px T-SOD b( NO) NC ( P > 0. 05), HL ( 0 d) NCHLDCSPS-LSPS-M SPS-H ( P > 0. 05) SPS-H b( MDA) NC ( P < ( 10) 28 d, 0. 01), SPS-L HL ( P ( P < ), NCNC-SHL g, HL 4. 0% 6. 8% 12. 3% 7. 6% 11. 0% 9. 5% SPS-LSPS-M SPS-H NCHL ( P > 0. 05),, NC ( P < 0. 05), HL, ( 11) DCSPS-LSPS-M ( P < ), DCSPS-LSPS-M < 0. 01),

8 ( X SD) Tab. 8 Effect of agaropectin on TC and TG in rats mmoll - 1 total cholesterol ( TC) 0 d 28 d triglyceride ( TG) 0 d 28 d ( NC) # ##aa ## ## ( NC-S) ## ## ## ## ( HL) * ** aa ** ** ( DC) ** ##ab ** * ##ab ( SPS-L) * ##ab ** ##ab ( SPS-M) ** ##ab ** ##ab ( SPS-H) ** ** ##ab ** ##ab : Note: HL Compared with HL. 9 ( X SD) Tab. 9 Effect of agaropectin on HDL-C and LDL-C in rats mmoll - 1 high-density lipoprotein ( HDL-C) 0 d 28 d low density lipoprotein ( LDL-C) 0 d 28 d ( NC) ## ## ## ## ( NC - S) ## ## ## ( HL) ** ** ** ** ab ( DC) ** * ##ab ** ##ab ( SPS-L) ** ** ##ab ** ##ab ( SPS-M) ** * ##ab ** ##ab ( SPS-H) ** * ##ab ** ##ab 10 ( X SD) Tab. 10 Effect of agaropectin on weight in rats /g body weight 0 d 7 d 14 d 21 d 28 d / g weight growth /% rate of weight growth ( NC) ab ( NC - S) * ab ( HL) ab ( DC) ab ( SPS-L) * # * # * # ab ( SPS-M) * # * # ab ( SPS-H) * * # * # ab SPS-L HL ( P < 0. 05), ( P < 0. 01), HL DC GSH-Px T-SOD, b( NO), b( MDA), ( P > 0. 05), NCNC-SSPS-H GSH-Px T-SOD, b ( NO), MDA, ( P < 0. 05), SPS-L HL GSH-Px, GSH-Px, NCNC-S DC ( P < 0. 05), SPS-LSPS-MSPS-H DC HL ( P < 0. 01), DCSPS-M HL ( P > ),, ; T-SOD

9 3 : 65, NCNC-SDCSPS-LSPS-MSPS-H HL ( P < 0. 01), HL DC ( P > 0. 05), HL DC ( P < 0. 01), < 0. 01), SPS-L DC ( P < 0. 05), T-SOD ; b( NO) NCNC-SDCSPS-LSPS-MSPS-H HL, HL DC ( P < 0. 01), ( P >0. 05), HL DC ( P < MDA( 12) 0. 05), NCNC-SSPS-L HL ( P b( MDA) b( NO), < 0. 05), SPS-MSPS-H HL GSH-Px T-SOD, ( P < ),, b ( NO), b( NO) ; b( MDA), HLSPS-L DC ( P > 0. 05), HL DC ( P 11 ( X SD) Tab. 11 Measurements of agaropectin on index of GSH-Px, T-SOD, NO and MDA in liver /g liver index b( ) / GSH-Px /Umg - 1 prot T-SOD / molg - 1 NO b( ) /nmolmg - 1 ( NC) ## ## ## ## ## ( NC-S) ## * ## * ## ## ## ( HL) ** ** ** ** ** ( DC) ## ## ## ## ** ## ( SPS-L) * ## ## # ** ## ** # ( SPS-M) ## ## # ## ** ## ( SPS-H) ## ## ## ## ** ## MDA 12 ( X SD) Tab. 12 Measurements of agaropectin on index of GSH-Px, T-SOD, NO and MDA in serum b( ) / GSH-Px / Umg - 1 prot T-SOD /molg - 1 NO b( ) / nmolmg - 1 ( NC) ** ## ## # ## ( NC-S) ** ## MDA ## # ## ( HL) * ** * ** ( DC) # ## # ## ( SPS-L) ## * ## ( SPS-M) # ## ## ## ( SPS-H) ## ## ## ## : Note: DC Compared with DC. 3 ml - 1, O 2 - OH DPPH,,, O 2 - OH DPPH [ 19],, O 2 - IC mgml - 1, OH IC mgml - 1, DPPH IC mg,,

10 66 9,, 2001., DNA,, [ 20 ],, 28 d,,,,,,,, [ J].,, ;,, [ 22 ], [ 12],,,, ; TCTG, HDL-C, LDL-C,,,,,,,,, TC TG [ 23 ] GSH-PxT- SOD, NO,,, MDA, -,, [ 21 ] : [ 1],. [ J]. [ 22]., 2012, 34( 3) : [ 2],,,. [ 22],. [ J] :, 2003, 28 ( 3 ) : [ 3]. [ D]. :, [ 4]. [ D]. :, [ 5] KIHO T, MORIMOTO H, KOBAYASHI T, et al. Effect of a polysaccharide ( TAP) from the fruiting bodies of Tremlla auranitia on glucose metabolism in mouse liver [ J]. Biomchnol Biochem, 2000, 64( 2) : 417. [ 6],,,. [ J]., 2010, 36 ( 5) : [ 7],,,. [ J]., 2000, 19( 3 ) : 33. [ 8],,., 2012, 27( 9 ) : [ 9]. [ J]., 1999( 2) : [ 10],. [ J]., 2010( 8) : [ 11] SHAMA O P, BHAT T K. DPPH antioxidant assay revisited[ J]. Food Chem, 2009, 113( 4 ) : [ D]. :, [ 13] SEZIK E, ASLAN M, YESILADA E, et al. Hypoglycaemic activity of Gentiana olivieri and isolation of the active constituent through bioassay-directed fractionation techniques [ J]. 2005, 76 ( 11 ) : Life Sci, [ 14]. [ 2003 ] 42 ( 2003 ) [ Z] : [ 15],,,. [ J]., 2010, 46 ( 5) : [ 16] SHARMA S B, NASIR A, PRABHU K M, et al. Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits[ J]. J Ethnopharmacol, 2003, 85 ( 2 /3) : [ 17],,. Fenton [ J]., 1996, 23 ( 2 ) : [ 18] JEON SM, BOK S H, JANGM K, et al. Antioxidative activity of maringin and lovastain in high cholesterol-fed rabbits [ J]. Sci, 2001, 69 ( 24 ) : [ 19] MARITIM A C, SANDERS R A, WATKINS J B. Diabetes, oxidative stress and antioxidants: a review[ J]. J Biochem Mol Toxicol, 2003, 17( 1) : Life [ 20],,. [ J]., 2012, 37( 6 ) : [ D]. :, [ J]., 2000, 23( 3) : [ 23]. [ D]. :

中草药 Chinese Traditional and Herbal Drugs 第 46 卷第 9 期 2015 年 5 月 1339 非酒精性脂肪性肝病 (nonalcoholic fatty liver disease,nafld) 是一种与胰岛素抵抗遗

中草药 Chinese Traditional and Herbal Drugs 第 46 卷第 9 期 2015 年 5 月 1339 非酒精性脂肪性肝病 (nonalcoholic fatty liver disease,nafld) 是一种与胰岛素抵抗遗 1338 中草药 Chinese Traditional and Herbal Drugs 第 46 卷第 9 期 2015 年 5 月九味肝泰胶囊对高脂饮食诱导大鼠非酒精性脂肪肝的治疗作用陈菲 1 2,, 艾国 3, 盛柳青 1, 麻佳蕾 1, 黄正明 1. 金华职业技术学院医学院, 浙江金华